F

Fluidigm Corp
F:FLB

Watchlist Manager
Fluidigm Corp
F:FLB
Watchlist
Price: 1.89 EUR 0.53% Market Closed
Market Cap: 700.1m EUR
Have any thoughts about
Fluidigm Corp?
Write Note

Fluidigm Corp
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Fluidigm Corp
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
F
Fluidigm Corp
F:FLB
Income from Continuing Operations
-$124.6m
CAGR 3-Years
-22%
CAGR 5-Years
-13%
CAGR 10-Years
-10%
Thermo Fisher Scientific Inc
NYSE:TMO
Income from Continuing Operations
$6.2B
CAGR 3-Years
-10%
CAGR 5-Years
11%
CAGR 10-Years
14%
Danaher Corp
NYSE:DHR
Income from Continuing Operations
$3.6B
CAGR 3-Years
-15%
CAGR 5-Years
11%
CAGR 10-Years
3%
Mettler-Toledo International Inc
NYSE:MTD
Income from Continuing Operations
$795.6m
CAGR 3-Years
2%
CAGR 5-Years
8%
CAGR 10-Years
9%
Agilent Technologies Inc
NYSE:A
Income from Continuing Operations
$1.3B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
19%
IQVIA Holdings Inc
NYSE:IQV
Income from Continuing Operations
$1.4B
CAGR 3-Years
22%
CAGR 5-Years
39%
CAGR 10-Years
16%
No Stocks Found

Fluidigm Corp
Glance View

Market Cap
703.6m EUR
Industry
Life Sciences Tools & Services

Fluidigm Corp. is engaged in the development, manufacture, and marketing of biotechnology tools for life sciences research. The company is headquartered in South San Francisco, California and currently employs 615 full-time employees. The company went IPO on 2011-02-10. The firm operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. The company markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits (ifcs), assays, and reagents. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.

FLB Intrinsic Value
0.67 EUR
Overvaluation 65%
Intrinsic Value
Price
F

See Also

What is Fluidigm Corp's Income from Continuing Operations?
Income from Continuing Operations
-124.6m USD

Based on the financial report for Sep 30, 2024, Fluidigm Corp's Income from Continuing Operations amounts to -124.6m USD.

What is Fluidigm Corp's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-10%

Over the last year, the Income from Continuing Operations growth was -65%. The average annual Income from Continuing Operations growth rates for Fluidigm Corp have been -22% over the past three years , -13% over the past five years , and -10% over the past ten years .

Back to Top